Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Isolinderalactone is a naturally occurring sesquiterpene lactone isolated from the root extract of *Lindera aggregata*. Preclinical publications describe it as an experimental small molecule with antineoplastic activity in cancer cell models, including colorectal cancer. In colorectal cancer cell lines, isolinderalactone has been reported to suppress proliferation and induce reactive oxygen species mediated stress responses leading to G2/M cell-cycle arrest, mitochondrial apoptosis, autophagy, and MAPK pathway activation. It does not appear to be an approved medicine or a clinically developed pharmaceutical product, and no specific commercial developer or manufacturer is clearly established from the provided evidence.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on isolinderalactone.